Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells

Area of Science:

• Immunology
• Cell Biology
• Transplantation Science

Background:

• Rapamycin is an immunosuppressive drug used to prevent organ transplant rejection.
• Operational tolerance has been observed in murine models treated with rapamycin.
• The direct impact of rapamycin on regulatory T (Tr) cells, vital for immune tolerance, remained unelucidated.

Purpose of the Study:

• To investigate the direct effect of rapamycin on regulatory T (Tr) cells.
• To determine if rapamycin can expand naturally occurring CD4(+)CD25(+)FoxP3(+) Tr cells.
• To assess the therapeutic potential of rapamycin-expanded Tr cells in transplantation.

Main Methods:

• In vitro expansion of murine CD4(+)CD25(+)FoxP3(+) Tr cells using rapamycin.
• In vitro suppression assays to evaluate the function of expanded Tr cells.
• In vivo allograft rejection models to assess the efficacy of Tr cell therapy.

Main Results:

• Rapamycin selectively expands naturally occurring CD4(+)CD25(+)FoxP3(+) Tr cells in vitro.
• Expanded Tr cells demonstrate suppressed syngeneic T cell proliferation in vitro.
• Rapamycin-expanded Tr cells effectively prevent allograft rejection in vivo.
• Rapamycin does not inhibit activation-induced cell death or proliferation of conventional CD4(+) T cells.

Conclusions:

• Rapamycin promotes the expansion of functional regulatory T (Tr) cells.
• This expansion mechanism offers a novel therapeutic strategy for T-cell-mediated diseases.
• Rapamycin-expanded Tr cells hold promise for ex vivo cellular therapy in transplantation and autoimmune conditions.